Generic placeholder image

Cardiovascular & Hematological Disorders-Drug Targets


ISSN (Print): 1871-529X
ISSN (Online): 2212-4063

Apixaban in Venous Thromboembolism in an Era of New Oral Anticoagulants

Author(s): Mohit K. Turagam, Poonam Velagapudi, Oluwaseun Adeola, Bhavana Chinnakotla and Martin A. Alpert

Volume 15, Issue 2, 2015

Page: [139 - 147] Pages: 9

DOI: 10.2174/1871529X1502151209120216

Price: $65


Several new oral anticoagulants (NOAC) have been recently studied and approved for the prevention and treatment of venous thromboembolism (VTE) which includes deep vein thrombosis and pulmonary embolism. Although, NOACs possess several advantages when compared to traditional therapy each has its own limitations; especially in the elderly and in patients with low body weight, renal impairment and in those with high risk of bleeding. Apixaban is a factor Xa inhibitor recently approved for the treatment and prevention of VTE in the United States. The purpose of this manuscript is to review describes the pharmacological properties of NAOC’s and to discuss clinical trial results and clinical applications of these agents in the prevention and treatment of VTE with special emphasis on the role of apixaban.

Keywords: Apixaban, venous thromboembolism, deep vein thrombosis, pulmonaryembolism, NOAC, novel anticoagulants, warfarin.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy